

CHEMICAL HERITAGE FOUNDATION

MARK D. FLEMING

The Pew Scholars Program in the Biomedical Sciences

Transcript of an Interview
Conducted by

Karen A. Frenkel


at

Children's Hospital
Boston, Massachusetts

on

1, 2, and 3 October 2007

(With Subsequent Corrections and Additions)



Mark D. Fleming

ACKNOWLEDGEMENT

This oral history is part of a series supported by a grant from the Pew Charitable Trusts based on the Pew Scholars Program in the Biomedical Sciences. This collection is an important resource for the history of biomedicine, recording the life and careers of young, distinguished biomedical scientists and of Pew Scholars Program in the Biomedical Sciences Advisory Committee members.

This oral history is made possible through the generosity of



CHEMICAL HERITAGE FOUNDATION
Oral History Program
FINAL RELEASE FORM

This document contains my understanding and agreement with the Chemical Heritage Foundation with respect to my participation in the audio-recorded interview conducted by Karen Frenkel on October 1-3, 2007. I have read the transcript supplied by Chemical Heritage Foundation.

1. The audio recording, corrected transcript, photographs, and memorabilia (collectively called the "Work") will be maintained by the Chemical Heritage Foundation and made available in accordance with general policies for research and other scholarly purposes.
2. I hereby grant, assign, and transfer to the Chemical Heritage Foundation all right, title, and interest in the Work, including the literary rights and the copyright, except that I shall retain the right to copy, use, and publish the Work in part or in full until my death.
3. The manuscript may be read and the audio recording(s) heard by scholars approved by the Chemical Heritage Foundation subject to the restrictions listed below. The scholar pledges not to quote from, cite, or reproduce by any means this material except with the written permission of the Chemical Heritage Foundation.
4. I wish to place the conditions that I have checked below upon the use of this interview. I understand that the Chemical Heritage Foundation will enforce my wishes until the time of my death, when any restrictions will be removed.

Please check one:

a. _____

No restrictions for access.

NOTE: Users citing this interview for purposes of publication are obliged under the terms of the Chemical Heritage Foundation Oral History Program to obtain permission from Chemical Heritage Foundation, Philadelphia, Pennsylvania.

b. _____

Semi-restricted access. (May view the Work. My permission required to quote, cite, or reproduce.)

c. _____


Restricted access. (My permission required to view the Work, quote, cite, or reproduce.)

This constitutes my entire and complete understanding.

(Signature) _____

Mark D. Fleming

(Date) _____


11/1/07

This interview has been designated as **Free Access**.


One may view, quote from, cite, or reproduce the oral history with the permission of CHF.

Please note: Users citing this interview for purposes of publication are obliged under the terms of the Chemical Heritage Foundation Oral History Program to credit CHF using the format below:

Mark D. Fleming, interview by Karen A. Frenkel at the Harvard Children's Hospital, Boston, Massachusetts, 1-3 October 2007 (Philadelphia: Chemical Heritage Foundation, Oral History Transcript # 378).



Chemical Heritage Foundation
Oral History Program
315 Chestnut Street
Philadelphia, Pennsylvania 19106



The Chemical Heritage Foundation (CHF) serves the community of the chemical and molecular sciences, and the wider public, by treasuring the past, educating the present, and inspiring the future. CHF maintains a world-class collection of materials that document the history and heritage of the chemical and molecular sciences, technologies, and industries; encourages research in CHF collections; and carries out a program of outreach and interpretation in order to advance an understanding of the role of the chemical and molecular sciences, technologies, and industries in shaping society.

MARK D. FLEMING

1965 Born in Poughkeepsie, New York on 4 November

Education

1987 A.B., molecular biology, Princeton University
1990 D.Phil., organic chemistry, University of Oxford, Oxford, England
1993 M.D., Harvard Medical School

Professional Experience

Harvard University School of Public Health
1990-1992 Medical Student Research Assistant in Cancer Biology

Brigham and Women's Hospital, Boston, Massachusetts
1990-1992 Resident in Anatomic Pathology
1995-1996 Fellow in Hematopathology
1996 Senior Resident in Surgical Pathology
1997- present Associate Pathologist

Children's Hospital, Boston, Massachusetts
1997-2000 Post-doctoral Fellow in Hematology/Oncology
1999-2005 Assistant in Pathology
2005- present Pathologist
2007 Vice Chairman, Department of Pathology
2007- present Interim Pathologist-in-Chief

Harvard Medical School
1993-1998 Clinical Fellow in Pathology
1998-2000 Instructor in Pathology
2000-2005 Assistant Professor in Pathology
2006- present Associate Professor in Pathology

Dana-Farber Cancer Institute, Boston, Massachusetts
1998- present Pathologist

Honors

1987 Marshall Scholarship, Oxford University, Oxford, England

- 1987 Senior Prize for Academic Excellence, Department of Molecular Biology,
Princeton University
- 1987 Phi Beta Kappa, Princeton University
- 1987 *Summa Cum Laude*, Princeton University
- 1993 Harold Lamport Biomedical Research Prize, Harvard Medical School
- 1993 *Magna Cum Laude*, Harvard Medical School
- 1997 American Society of Hematology Travel Award
- 1998 American Liver Foundation Research Fellowship
- 1998 American Society of hematology Fellow Scholar Award
- 1999 Pew Scholar in the Biomedical Sciences
- 2004 Ramzi Cotran Teaching Award, Children's Hospital

ABSTRACT

Mark D. Fleming begins the interview discussing his childhood, which was dominated by his father's job at IBM [International Business Machines]. Fleming moved to various communities in the Eastern United States, where the majority of his friends also had fathers working for IBM; a scientific and technological atmosphere pervaded his childhood. Fleming discussed his matriculation at Princeton University and the academic influence of organic chemistry professor Maitland Jones, Jr. Throughout his undergraduate career, Fleming conducted research during summers at the University of Vermont, where he met his future wife as well as where he developed an interest in blood research. Following graduation from Princeton, Fleming received a Marshall Scholarship, which allowed him to pursue D.Phil. work with Sir Jack E. Baldwin at the University of Oxford; Fleming described the differences between scientific research in Europe and the United States in some detail. Following his D.Phil. work, Fleming undertook medical training at the Harvard Medical School's Health, Sciences, and Technology Program, which was academically rigorous and stimulating. He developed into a clinically-oriented research pathologist, beginning with his work in Laurie Glimcher's laboratory at the Harvard University School of Public Health and continuing into his post-doctoral research with Nancy Andrews at Children's Hospital. Due to a unique job offer at Children's Hospital, Fleming smoothly transitioned from post-doctoral researcher to full-time principal investigator. Throughout the interview, Fleming discussed issues related to funding and laboratory management and the manner in which he encourages the academic growth of his own research students. The interview concludes with a discussion of broader issues in the biomedical sciences including increasing the racial diversity of students and of faculty in the sciences, scientific literacy, and collaborations.

INTERVIEWER

Karen A. Frenkel is a writer, documentary producer, and author specializing in science and technology and their impacts on society. She wrote *Robots: Machines in Man's Image* (Harmony 1985) with Isaac Asimov. Her articles have appeared in many magazines and newspapers including *The New York Times*, *CyberTimes*, *Business Week*, *Communications Magazine*, *Discover*, *Forbes*, *New Media*, *Personal Computing*, *Scientific American*, *Scientific American MIND*, *The Village Voice*, and *Technology Review*. Ms. Frenkel's award-winning documentary films, *Net Learning* and *Minerva's Machine: Women and Computing* aired on Public Television. She has been an interviewer for Columbia University's Oral History Research Center's 9/11 Narrative and Memory project, The National Press Foundation's Oral History of Women in Journalism, and the International Psychoanalytic Institute for Training and Research's Oral History. Professional memberships include: The Authors Guild, National Association of Science Writers, Writer's Guild of America East, and New York Women in Film and Television: Past Member of the Board and Director of Programming. Her website is www.Karenafrenkel.com

TABLE OF CONTENTS

Childhood	1
Father's career at IBM. Moving to various IBM locations including Manassas, Virginia and South Burlington, Vermont. Early interests in natural science.	
College Education	13
Princeton University. Molecular Biology. Organic Chemistry. Summer research at the University of Vermont. Burgeoning interest in blood research. Meeting his wife.	
Graduate School	17
Marshall Scholarship to study at Oxford University. Sir Jack Baldwin's research group. Discovering a bifunctional enzyme. Dealings with Eli Lilly and Company. Scientific ethics and publishing. Transitions between molecular biology and chemistry.	
Medical School and Research	28
Harvard Medical School. The Health, Sciences, and Technology Program. Rigorous scientific and collaborative atmosphere. Medicine as science. Research with Laurie Glimcher. Children's Hospital Boston. Post-doctorate with Nancy Andrews. Long-standing collaboration. Research on NFE2. Medical and scientific ethics.	
Principal Investigator	39
Children's Hospital Boston. Transition from post-doctoral research to Principal Investigator. Ramzi Cotran. PI style. Pew Biomedical Scholars Award.	
Funding	44
Grants versus contracts. NIH funding. Private Foundation Funding. Funding people not projects	
Principal Investigator	47
Interim Chairman. Publishing. Collaborations. Laboratory management. Scooping other research groups. Teaching.	
Family Life	61
Wife's Ph.D. in cell biology. Balancing careers and children. Time in Vermont.	

Biomedical Sciences	63
Funding. Service to the community. Scientific literacy. Consulting. Immunohistochemistry and Pathology. Collaborations. Scientific Outreach.	
Index	84

INDEX

A

Abbas, Abul K., 33
AIDS [Acquired Immune Deficiency Syndrome], 10, 11, 19
Amherst College, 9, 10
Andrews, Nancy C., 34, 35, 36, 37, 38, 39, 40, 41, 42, 53, 54, 55, 60, 61, 79, 80
Anemia, 36, 47, 49, 51, 58, 71
Arkansas, 81

B

Baldwin, Jack, 21, 24, 25, 35
Basic Science, 27
Beacon Hill, Massachusetts, 19
Belton, Curt, 7
Bhopal, India, 16
Biology, 5, 7, 10, 11, 12, 13, 17, 18, 21, 22, 29, 43, 55, 56, 58, 60, 73, 80
 cell biology, 40, 61
 human biology, 17
 marine biology, 10
 microbiology, 31
 molecular biology, 10, 12, 17, 22, 33, 55, 60
 organismal biology, 12
Biotechnology, 10
Blood, 12, 13, 14, 18, 30, 31, 39, 47, 50, 58, 66, 70, 71, 74
Bone Marrow, 8, 14, 30, 31
Bonner, John, 12
Boston, Massachusetts, 13, 19, 33, 38, 61, 62, 64, 68, 70, 74, 75, 81
Bowdoin College, 9, 10
Brigham and Women's Hospital, 40, 69
Bryn Mawr College, 15

C

Cambridge University, 32
Canada, 70
Cancer, 36, 51, 65
Cephalosporins, 22
Chemistry, 12, 16, 17, 18, 21, 22, 24, 32
 organic chemistry, 16, 17, 21, 32
Chiang, Anne, 16
Children's Hospital Boston, 33, 34, 38, 40, 41, 42, 61, 65, 67, 68, 69, 73
China, 72, 79
Chromosome, 70
Clinical Trials, 26
Collaborations, 25, 31, 34, 35, 39, 54, 55, 69, 70
Collins, Tucker, 33, 74
Competition, 9, 13, 17, 19, 34, 57, 71
Cotran, Ramzi, 39, 40, 41, 42, 47
Crossing Jordan, 29
CSI, 29, 31

D

Daley, George Q., 73
Dana-Farber Cancer Institute, 34, 69
Dartmouth College, 9, 10
DNA, 12, 17, 77
 replication, 12, 17
Duke University, 34, 37, 40
 Medical School, 34

E

Ehrlich, Ygal, 13
Eli Lilly and Company, 22, 23, 24, 25, 26
Embryos, 73
Emerson, Ralph Waldo, 8

Engineering, 1
England, 9, 17, 21, 23, 24, 25, 28, 29, 58,
67, 72
Enzymes, 22, 23, 25, 27, 58
Essex Junction, Vermont, 6

F

Fishkill, New York, 1
Fleming, John V., 15
France, 10, 12
Funding, 26, 37, 39, 40, 41, 44, 45, 46, 47,
49, 62, 63, 69, 70, 71, 76, 77, 78

G

Gallo, Robert C., 10
Genes, 17, 27, 36, 43, 47, 48, 49, 51, 58, 59,
70
 cloning, 17, 22, 27, 38, 42, 43, 79
Genetics, 12, 17, 30, 42, 49, 55, 56, 58, 65,
70, 82
Genome Canada, 70
Glimcher, Laurie, 32, 33, 42, 79
Global Health, 71, 72
Globalization, 71, 72
Google, 57, 58, 59
Gould, Stephen Jay, 12
Grant, Barbara, 14, 19
Greenspan, Ralph, 12

H

Harvard Medical School, 20, 21, 26, 28, 39,
40, 60, 61, 62, 67, 70, 79, 80
 HST [Health Sciences and Technology
 Division], 28, 29, 30, 33
Heller, Miles, 9
Hematology, 8, 14, 18, 30, 34, 36, 42, 60,
66, 73, 79
Hematopathology, 40, 68, 69, 70, 82
Hemochromatosis, 36
Hemoglobin, 39
Hereditary Spherocytosis, 51
Histology, 65
HIV [Human Immunodeficiency Virus], 20
Howard Hughes Medical Institute, 47, 77

I

IBM [International Business Machine], 1, 2,
3, 6
Immune Disease Institute, 61
Immunohistochemistry, 66, 67
Immunology, 31, 32, 33
Indiana, 23
Infectious Disease, 31
Institute for Biomedical Research, 61
Insulin, 10
Iron, 29, 36, 38, 39, 43, 47, 48, 55, 56, 57,
58, 66, 67, 70, 71, 79

J

Jackson Labrotory Bar Harbor, Maine, 56
Japan, 72
John D. and Catherine T. MacArthur
 Foundation, 77
Jones, Maitland, 16, 22

K

Kennedy, John F., 21, 56
Kornecki, Elizabeth, 13
Kuhn, Thomas S., 22
Kuhnian Revolutions, 22, 77

L

Lee, Jeannie T., 70
Leukemia, 82
Litz, A. Walton, 15, 18
Lodish, Harvey F., 70
Los Angeles, California, 10

M

M.D./Ph.D. Joint Program, 18, 31
Manassas, Virginia, 1, 2, 6
Manser, Tim, 18, 32
Marshall Scholarship, 17, 18, 19, 20, 21, 32
Martin, Michael, 7, 8, 9
Mathematics, 74
Medical Genetics, 30
Melanoma, 41
Merck & Co., 62, 66, 75
Meselson, Mathew S., 12, 17

Meyers, Mike, 83
Microcytic Anemia, 36, 38, 79
MIT [Massachusetts Institute of Technology], 21, 28
Mitchell, Richard N., 29
mk. See Microcytic Anemia
Montagnier, Luc, 10
Mouse Model System, 17, 36, 42, 43, 47, 48, 49, 50, 51, 52, 55, 56, 57, 58, 65, 70
Mutagenesis, 27

N

Nathan, David G., 34
Natural Sciences, 5, 7, 10, 52
Nature, 54, 79, 81
Nature Genetics, 54
New Brunswick, Canada, 64
New Jersey, 75
New York Times, 11
NIH [National Institutes of Health], 37, 44, 45, 46, 47, 64, 71, 76, 78
K08 Funding, 36, 41, 63, 64
R01 funding, 45, 46

O

Oncology, 30, 36
Orkin, Stuart H., 36
Oxford University, 17, 19, 21, 22, 23, 26, 32
Oxygen, 32, 39

P

Pakistan, 71
Parasitosis, 71
Pathology, 5, 8, 14, 26, 29, 30, 31, 36, 39, 41, 42, 49, 51, 55, 60, 63, 64, 65, 66, 68, 69, 79
anatomic, 31
clinical, 31
Pediatrics, 69
Penicillin, 22, 27
Penicillium, 22
Pennsylvania, 15, 75

Pew Charitable Trusts, 37, 38, 41, 42, 44, 47, 56, 62, 68, 70, 77, 82, 83
Pew Scholars Program in the Biomedical Sciences, 17, 18, 21, 37, 38, 41, 63, 68, 70, 71
Physics, 2, 29, 30, 74, 75
Physiology, 47, 58
Plasmids, 17
Platelets, 13, 14
Post-Doctorate, 33, 34, 36, 38, 39, 43, 44, 48, 50, 52, 53, 60, 63
Poughkeepsie, New York, 1, 6
Princeton University, 9, 10, 11, 13, 15, 16, 17, 18, 35
Proteins, 36, 47, 55, 58
NFE2, 36
Psychiatry, 13
Publishing, 13, 14, 16, 22, 24, 25, 26, 27, 28, 33, 34, 35, 39, 40, 43, 44, 47, 52, 53, 54, 55, 56, 57, 58, 59, 69, 79, 81, 82

Q

Qiagen, 77
Quincy M.E., 29

R

Reagan, Ronald W., 56
Reston, Virginia, 1, 3, 5, 7
Rheumatology, 31
Rhodes Scholarship, 17, 18, 29
Rimel, Rebecca W., 83
Rome, New York, 1
RPI [Rensselaer Polytechnic Institute], 4

S

Schirmer, Bob, 7
Schistosomiasis, 71
Science, 13, 14, 22, 79
Scientific Education, 24
September 11th, 2001, 56, 57
Silver, Lee M., 17
Sorell, Ann, 7
South Burlington, Vermont, 7
South Korea, 73

Stahl, Franklin W., 12, 17
Stevens, Wallace, 15
Subfusc, 32
Summers, Lawrence H., 80
Sutherland, 21, 24, 25
Syracuse, New York, 1

T

Teaching, 7, 16, 17, 22, 23, 29, 59, 60, 61,
68, 69, 74
The Scarlet Letter, 9
Tian, Meng, 72
Transferrin, 56, 58, 70
Tufts University, 40, 61

U

Union Carbide Corporation, 16
University of Pennsylvania, 20
University of Vermont, 9, 20

V

Valium, 13
Vermont, 3, 5, 6, 7, 9, 10, 13, 14, 15, 20, 62,
64, 80, 81
Vonderheide, Robert H., 29

W

Washington, D.C., 3
White, Ryan, 19, 20
World Trade Center, 56
World War II, 17